ROIVW (ROIVW) News
Follow ROIVW (ROIVW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ROIV ROIVW - Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
ROIV ROIVW - Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
NEWS | Sep 23, 2026, 11:00 AM UTC
M
Roivant announces positive PHocus results for mosliciguat
Roivant says its PHocus study of mosliciguat in PH-ILD patients produced positive results.
EQUITY | Sep 08, 2026, 10:00 AM UTC
H
ROIV ROIVW - Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associa
ROIV ROIVW - Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday,
GEOPOLITICS | Sep 06, 2026, 05:00 AM UTC
M
Priovant announces FDA approval of LISRAYA for dermatomyositis adults
Priovant says the FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis; it is now available in the U.S.
REGULATION | Aug 27, 2026, 07:29 PM UTC
L
ROIV ROIVW - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis - Click For Relea
ROIV ROIVW - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
EQUITY | Aug 26, 2026, 03:11 PM UTC
L
ROIV ROIVW - Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
ROIV ROIVW - Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
EARNINGS | Aug 06, 2026, 11:01 AM UTC
M
Priovant Enrolls First Patients In Brepocitinib Phase 3 Study
Priovant starts Phase 3 trial for Brepocitinib
EQUITY | Aug 06, 2026, 11:00 AM UTC